Sensitive Phenotypic Detection of Minor Drug-resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptase Variants

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2005 Nov 8

PMID 16272507

Citations 6

Authors

Dwight V Nissley

Elias K Halvas

Nicole L Hoppman

David J Garfinkel

John W Mellors

Jeffrey N Strathern

Affiliations

Soon will be listed here.

Abstract

Detection of drug-resistant variants is important for the clinical management of human immunodeficiency virus type 1 (HIV-1) infection and for studies on the evolution of drug resistance. Here we show that hybrid elements composed of the Saccharomyces cerevisiae retrotransposon Ty1 and the reverse transcriptase (RT) of HIV-1 are useful tools for detecting, monitoring, and isolating drug-resistant reverse transcriptases. This sensitive phenotypic assay is able to detect nonnucleoside reverse transcriptase inhibitor-resistant RT domains derived from mixtures of infectious molecular clones of HIV-1 in plasma and from clinical samples when the variants comprise as little as 0.3 to 1% of the virus population. Our assay can characterize the activities and drug susceptibilities of both known and novel reverse transcriptase variants and should prove useful in studies of the evolution and clinical significance of minor drug-resistant viral variants.

Citing Articles

Minority variants of drug-resistant HIV.

Gianella S, Richman D J Infect Dis. 2010; 202(5):657-66.

PMID: 20649427 PMC: 2916955. DOI: 10.1086/655397.

Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C.

Rowley C, Boutwell C, Lockman S, Essex M J Virol Methods. 2008; 149(1):69-75.

PMID: 18295909 PMC: 2927209. DOI: 10.1016/j.jviromet.2008.01.005.

Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations.

Paredes R, Marconi V, Campbell T, Kuritzkes D J Virol Methods. 2007; 146(1-2):136-46.

PMID: 17662474 PMC: 4195598. DOI: 10.1016/j.jviromet.2007.06.012.

Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT.

Nissley D, Radzio J, Ambrose Z, Sheen C, Hamamouch N, Moore K Biochem J. 2007; 404(1):151-7.

PMID: 17286555 PMC: 1868834. DOI: 10.1042/BJ20061814.

MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples.

Svarovskaia E, Moser M, Bae A, Prudent J, Miller M, Borroto-Esoda K J Clin Microbiol. 2006; 44(11):4237-41.

PMID: 17005757 PMC: 1698293. DOI: 10.1128/JCM.01512-06.

References

OMeara D, Wilbe K, Leitner T, Hejdeman B, Albert J, Lundeberg J . Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. J Clin Microbiol. 2001; 39(2):464-73. PMC: 87760. DOI: 10.1128/JCM.39.2.464-473.2001. View

Lindstrom A, Albert J . A simple and sensitive 'in-house' method for determining genotypic drug resistance in HIV-1. J Virol Methods. 2002; 107(1):45-51. DOI: 10.1016/s0166-0934(02)00188-x. View

Cunningham S, Ank B, Lewis D, Lu W, Wantman M, Dileanis J . Performance of the applied biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples. J Clin Microbiol. 2001; 39(4):1254-7. PMC: 87920. DOI: 10.1128/JCM.39.4.1254-1257.2001. View

Shafer R, Hertogs K, Zolopa A, Warford A, Bloor S, Betts B . High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol. 2001; 39(4):1522-9. PMC: 87964. DOI: 10.1128/JCM.39.4.1522-1529.2001. View

Jarmy G, Heinkelein M, Weissbrich B, Jassoy C, Rethwilm A . Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system. J Med Virol. 2001; 64(3):223-31. DOI: 10.1002/jmv.1040. View

Fontaine E, Riva C, Peeters M, Schmit J, Delaporte E, Van Laethem K . Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J. J Acquir Immune Defic Syndr. 2001; 28(3):254-8. DOI: 10.1097/00042560-200111010-00008. View

Shafer R . Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev. 2002; 15(2):247-77. PMC: 118066. DOI: 10.1128/CMR.15.2.247-277.2002. View

Hammer S, Vaida F, Bennett K, Holohan M, Sheiner L, Eron J . Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA. 2002; 288(2):169-80. DOI: 10.1001/jama.288.2.169. View

Dybul M, Fauci A, Bartlett J, Kaplan J, Pau A . Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med. 2003; 137(5 Pt 2):381-433. DOI: 10.7326/0003-4819-137-5_part_2-200209031-00001. View

10.

Hirsch M, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes D, DAquila R . Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003; 37(1):113-28. DOI: 10.1086/375597. View

11.

Wormit A, Traub M, Florchinger M, Neuhaus H, Mohlmann T . Characterization of three novel members of the Arabidopsis thaliana equilibrative nucleoside transporter (ENT) family. Biochem J. 2004; 383(Pt 1):19-26. PMC: 1134039. DOI: 10.1042/BJ20040389. View

12.

Hoffman C, Winston F . A ten-minute DNA preparation from yeast efficiently releases autonomous plasmids for transformation of Escherichia coli. Gene. 1987; 57(2-3):267-72. DOI: 10.1016/0378-1119(87)90131-4. View

13.

Hizi A, McGill C, Hughes S . Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants. Proc Natl Acad Sci U S A. 1988; 85(4):1218-22. PMC: 279738. DOI: 10.1073/pnas.85.4.1218. View

14.

Curcio M, Garfinkel D . Single-step selection for Ty1 element retrotransposition. Proc Natl Acad Sci U S A. 1991; 88(3):936-40. PMC: 50929. DOI: 10.1073/pnas.88.3.936. View

15.

Boyer P, Ferris A, Hughes S . Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1. J Virol. 1992; 66(2):1031-9. PMC: 240806. DOI: 10.1128/JVI.66.2.1031-1039.1992. View

16.

Sharon G, Burkett T, Garfinkel D . Efficient homologous recombination of Ty1 element cDNA when integration is blocked. Mol Cell Biol. 1994; 14(10):6540-51. PMC: 359184. DOI: 10.1128/mcb.14.10.6540-6551.1994. View

17.

Coffin J . HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995; 267(5197):483-9. DOI: 10.1126/science.7824947. View

18.

Frenkel L, Wagner 2nd L, Atwood S, Cummins T, Dewhurst S . Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. J Clin Microbiol. 1995; 33(2):342-7. PMC: 227945. DOI: 10.1128/jcm.33.2.342-347.1995. View

19.

Gietz R, Schiestl R, Willems A, Woods R . Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure. Yeast. 1995; 11(4):355-60. DOI: 10.1002/yea.320110408. View

20.

Mansky L, Temin H . Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995; 69(8):5087-94. PMC: 189326. DOI: 10.1128/JVI.69.8.5087-5094.1995. View